Drug Discovery World (DDW), the Quarterly Business Review of Drug Discovery & Development

LATEST ISSUE: SPRING 2017 Archive

The Discoverome, creative destruction of barriers for faster to patient medicines R&D

By Chris Molloy

Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Pharma Derisking, approaches to reduce liability to major metabolically-driven causes of drug attrition

By Guy Webber

Intelligent application of early in vitro testing can help mitigate major drug development risks.

Spheroids rapidly becoming a preferred 3D culture format

By Dr John Comley

There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture.

Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

By Dr Philip Dube

Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.

Three-dimensional cell culture: a rapidly emerging technique for drug discovery

By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen

Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Immuno-Oncology's Biomarker Dilemma - How to add value in an uncertain development landscape

By Dr Rachel Laing and Olivier Lesueur

Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies.

Monitoring the balance between immune repression and stimulation in cancer immunotherapy

By Dr Peter Schulz-Knappe and Dr Georg Lautscham

Cancer remains one of the main causes of death worldwide, yet recent strides have been made in the form of new cancer immunotherapies.

83% of Life Science Leaders Believe Blockchain will be Adopted Within Five Years, Finds Survey from The Pistoia Alliance

The Pistoia Alliance is calling on the pharmaceutical and technology industries to support greater collaboration around blockchain initiatives.

QS Pharma receives approval from European Medicines Agency for commercial manufacture

QS Pharma, which was acquired by Quotient Clinical in February 2017, announced it has received approval from the European Medicines Agency (EMA) to manufacture certain medicinal products for commercial use in Europe.

Optibrium Introduces StarDrop 6.4 with Universal Pose Generation Interface

Optibrium, a developer of software for small molecule drug discovery, has announced the launch of version 6.4 of the StarDrop platform.

Bioconjugation specialist Innova Biosciences acquired by SYGNIS AG

Innova Biosciences, a specialist provider of bioconjugation products and services, has been fully acquired by SYGNIS AG, for EUR 8 million in cash and 3.5 million in shares.

New Single Quadrupole Mass Spectrometer and Specialized Columns Designed to Deliver Reproducible and Robust Separations, Increase Analytical Accuracy

Thermo Fisher Scientific Inc., today announced new technologies that are designed to allow analytical chemists to obtain high-resolution separations with outstanding sensitivity and reproducibility.

LifeArc (previously known as MRC Technology), today announced ambitious plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research.

	Drug Discovery	Business	Chemistry	Enabling Technologies
	Informatics	Personalised Medicine	Screening	Therapeutics

	SpectraMax i3 Multi-Mode Detection System See how you can do more with your microplate reader than you ever imagined.

	Bioanalysis of Oxytocin Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform